Quantification of glutamate and glutamine using constant-time point-resolved spectroscopy at 3T

NMR in Biomedicine

Volumn 26, Issue 2, 2013, Pages 164-172

  Gu, Meng ^a,b   Zahr, Natalie M ^b   Spielman, Daniel M ^a   Sullivan, Edith V ^b,c   Pfefferbaum, Adolf ^b   Mayer, Dirk ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Constant time point resolved spectroscopy (CT PRESS); Glutamate (Glu); Glutamine (Gln); Metabolite quantification; MRS

Indexed keywords

BASIS SETS; CLINICAL SCANNERS; COMBINED RESONANCE; CONSTANT-TIME POINT-RESOLVED SPECTROSCOPY (CT-PRESS); DEPHASING; DIFFERENTIAL CONTRIBUTION; GLUTAMATE (GLU); GLUTAMINE (GLN); IN-VIVO; INHOMOGENEITIES; MAGNITUDE SPECTRUM; METABOLITE CONCENTRATIONS; MRS; TIME DOMAIN;

AMINO ACIDS; ETHANOL; METABOLITES; PRESSES (MACHINE TOOLS); RATS; SEPARATION; VAPORS;

BIOMOLECULES;

ALCOHOL; GLUTAMIC ACID; GLUTAMINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CONCENTRATION (PARAMETERS); CONSTANT TIME POINT RESOLVED SPECTROSCOPY; CONTROLLED STUDY; IN VIVO STUDY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOFREQUENCY; RAT;

ALGORITHMS; ANIMALS; BRAIN CHEMISTRY; ETHANOL; GLUTAMIC ACID; GLUTAMINE; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTRANSMITTER AGENTS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

RATTUS;

EID: 84872613042     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2831     Document Type: Article

References (42)

1. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 2004; 45(5): 583-595.
2. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004; 73(1): 1-60.
3. Ramadan S, Mountford C. Two-dimensional magnetic resonance spectroscopy on biopsy and in vivo. In: Annual Reports on NMR Spectroscopy, Webb GA (ed.). Academic Press: Burlington, MA; 2009, pp. 161-199.
4. Siggins GR, Martin G, Roberto M, Nie Z, Madamba S, De Lecea L. Glutamatergic transmission in opiate and alcohol dependence. Ann. N. Y. Acad. Sci. 2003; 1003: 196-211.
5. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann. N. Y. Acad. Sci. 1987; 508: 333-348.
6. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn. Reson. Med. 1989; 9(1): 79-93.
7. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
8. Choi C, Coupland NJ, Bhardwaj PP, Malykhin N, Gheorghiu D, Allen PS. Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 Tesla. Magn. Reson. Med. 2006; 55(5): 997-1005.
9. Thompson RB, Allen PS. A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: its application to glutamate. Magn. Reson. Med. 1998; 39(5): 762-771.
10. Yang S, Hu J, Kou Z, Yang Y. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T. Magn. Reson. Med. 2008; 59(2): 236-244.
11. 1H MR spectroscopy: strong coupling effects in vitro and in vivo. Magn. Reson. Imaging 1995; 13(6): 853-869.
12. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3 T. Magn. Reson. Med. 2004; 51(3): 435-440.
13. Jensen JE, Licata SC, Ongur D, Friedman SD, Prescot AP, Henry ME, Renshaw PF. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009; 22(7): 762-769.
14. Schulte RF, Boesiger P. ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. NMR Biomed. 2006; 19(2): 255-263.
15. Dreher W, Leibfritz D. Detection of homonuclear decoupled in vivo proton NMR spectra using constant time chemical shift encoding: CT-PRESS. Magn. Reson. Imaging, 1999; 17(1): 141-150.
16. Mayer D, Spielman DM. Detection of glutamate in the human brain at 3T using optimized constant time point resolved spectroscopy. Magn. Reson. Med. 2005; 54(2): 439-442.
17. Zahr NM, Mayer D, Vinco S, Orduna J, Luong R, Sullivan EV, Pfefferbaum A. In vivo evidence for alcohol-induced neurochemical changes in rat brain without protracted withdrawal, pronounced thiamine deficiency, or severe liver damage. Neuropsychopharmacology 2009; 34(6): 1427-1442.
18. Dreher W, Busch E, Leibfritz D. Changes in apparent diffusion coefficients of metabolites in rat brain after middle cerebral artery occlusion measured by proton magnetic resonance spectroscopy. Magn. Reson. Med. 2001; 45(3): 383-389.
19. Schulte RF, Trabesinger AH, Boesiger P. Chemical-shift-selective filter for the in vivo detection of J-coupled metabolites at 3 T. Magn. Reson. Med. 2005; 53(2): 275-281.
20. Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object-oriented programming approach. J. Magn. Reson. A 1994; 106: 75-105.
21. Maudsley AA, Govindaraju V, Young K, Aygula ZK, Pattany PM, Soher BJ, Matson GB. Numerical simulation of PRESS localized MR spectroscopy. J. Magn. Reson. 2005; 173(1): 54-63.
22. Slotboom JMA, Bovee WMMJ. The effects of frequency-selective RF pulses on J-coupled spin 1/2 systems. J. Magn. Reson. A 1994; 108(1): 38-50.
23. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13(3): 129-153.
24. Pfefferbaum A, Adalsteinsson E, Bell RL, Sullivan EV. Development and resolution of brain lesions caused by pyrithiamine- and dietary-induced thiamine deficiency and alcohol exposure in the alcohol-preferring rat: a longitudinal magnetic resonance imaging and spectroscopy study. Neuropsychopharmacology 2007; 32(5): 1159-1177.
25. Dreher W, Leibfritz D. On the use of two-dimensional-J NMR measurements for in vivo proton MRS: measurement of homonuclear decoupled spectra without the need for short echo times. Magn. Reson. Med. 1995; 34(3): 331-337.
26. Nagayama K, Bachmann P, Wuthrich K, Ernst RR. Use of cross-sections and of projections in 2-dimensional NMR-spectroscopy. J. Magn. Reson. 1978; 31(1): 133-148.
27. Bax A, Freeman R. Investigation of complex networks of spin-spin coupling by two-dimensional NMR. J. Magn. Reson. 1981; 44(3): 542-561.
28. Mayer D, Dreher W, Leibfritz D. Fast U-FLARE-based correlation-peak imaging with complete effective homonuclear decoupling. Magn. Reson. Med. 2003; 49(5): 810-816.
29. 1H magnetic resonance spectroscopic imaging. Distribution of metabolites in normal brain and postmortem changes. NMR Biomed. 1993; 6(5): 311-317.
30. 1H-containing metabolites in rat brain after focal ischemia. NMR Biomed. 1995; 8(6): 245-252.
31. Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002; 13(1): 183-186.
32. Lentz MR, Kim WK, Lee V, Bazner S, Halpern EF, Venna N, Williams K, Rosenberg ES, González RG. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009; 72(17): 1465-1472.
33. Moore GJ, Galloway MP. Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol. Bull. 2002; 36(2): 5-23.
34. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 2007; 41(8): 625-634.
35. Simister RJ, McLean MA, Salmenpera TM, Barker GJ, Duncan JS. The effect of epileptic seizures on proton MRS visible neurochemical concentrations. Epilepsy Res. 2008; 81(1): 36-43.
36. 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res. 2006; 147(1): 1-25.
37. Mohamed MA, Barker PB, Skolasky RL, Selnes OA, Moxley RT, Pomper MG, Sacktor NC. Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn. Reson. Imaging 2010; 28(9): 1251-1257.
38. Jalan R, Turjanski N, Taylor-Robinson SD, Koepp MJ, Richardson MP, Wilson JA, Bell JD, Brooks DJ. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 2000; 46(4): 546-552.
39. Mohanachari V, Reddy KS, Indira K. Metabolic fate of ammonia in the rat after ethanol loading. Toxicol. Lett. 1984; 20(2): 225-228.
40. Cooper AJ, Plum F. Biochemistry and physiology of brain ammonia. Physiol. Rev. 1987; 67(2): 440-519.
41. Bondy SC, Guo SX. Regional selectivity in ethanol-induced pro-oxidant events within the brain. Biochem. Pharmacol. 1995; 49(1): 69-72.
42. Zou J, Wang YX, Dou FF, Lu HZ, Ma ZW, Lu PH, Xu XM. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 2010; 56(4): 577-584.